Figure 4 | Scientific Reports

Figure 4

From: Identifying chemopreventive agents for obesity-associated cancers using an efficient, 3D high-throughput transformation assay

Figure 4

IGF1R inhibitors prevent FGF2-stimulated transformation whereas efficacy of HMG-CoA reductase inhibitors varies. (A) Fluvastatin (Fluv), simvastatin (Sim), rosuvastatin (Rosu), PPP, and NVP-ADW742 (NVP) significantly attenuated FGF2 (5 ng/mL)-stimulated transformation of JB6 P+ cells (2,000 cells/well) at 5.0 µM. Colonies were counted via automated counting using the Cytation 3 imaging reader from Biotek using Gen5 3.04 software. Seven pictures were taken every 100 microns and superimposed together by the zprojection function. (B) Fluvastatin (Fluv), rosuvastatin (Rosu), atorvastatin (Ator), and NVP-ADW742 (NVP) significantly attenuated FGF2 (30 ng/mL)-stimulated transformation of MCF-10A cells (1,000 cells/well) at 0.5 and 2.5 µM. Simvastatin (Sim) was significant at 2.5 µM. Each treatment group had three replicates and analyzed by one-way ANOVA with multiple comparisons (*p < 0.05; **p < 0.01).

Back to article page